5-Amino-1MQ vs Pinealon
Both 5-Amino-1MQ and Pinealon are used for longevity. Here's how their evidence, dosing, and regulatory status actually compare.
5-Amino-1MQ
Evidence C+5-Amino-1-Methylquinolinium
A small-molecule NNMT inhibitor that has produced fat loss and improved muscle stem-cell function in obese rodents. No human RCTs yet.
View full 5-Amino-1MQ profile →Pinealon
Evidence CPinealon (EDR)
A short tripeptide developed in Russia for cognitive aging and oxidative stress. Limited Western clinical evidence.
View full Pinealon profile →Side-by-Side
| Attribute | 5-Amino-1MQ | Pinealon |
|---|---|---|
| Evidence Grade | C+ | C |
| FDA Status | Not FDA-approved — small-molecule research compound (NNMT inhibitor) | Not FDA-approved — Russian-origin research peptide |
| Typical Dose | 50–150 mg orally daily (research-only) | 5–10 mg daily for 10–20 days (subcutaneous, cycled) |
| Clinics Indexed | 31 | 9 |
| Categories | fat-loss, longevity | cognitive, longevity |
Key reported benefits — 5-Amino-1MQ
- ✓NNMT inhibition
- ✓Fat-mass reduction (preclinical)
- ✓Muscle stem-cell support
Key reported benefits — Pinealon
- ✓Cognitive function (preclinical)
- ✓Reduced oxidative damage
- ✓Sleep/circadian effects
Educational use only
This comparison is for educational purposes and not medical advice. Peptide selection should be made with a licensed medical professional based on your individual goals, health history, and current evidence quality.